Encompass Health Corporation (NYSE:EHC) Stock Has Consensus Price Target of $148.50 According to Analysts

Encompass Health Corporation (NYSE:EHC) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $148.50.

Several brokerages have recently weighed in on EHC. Barclays raised their target price on Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. TD Cowen boosted their target price on Encompass Health from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. UBS Group upped their price target on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Encompass Health from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, September 26th.

Encompass Health Stock Performance

Shares of EHC stock opened at $126.36 on Monday. The company has a market cap of $12.47 billion, a P/E ratio of 20.58, a PEG ratio of 2.52 and a beta of 0.74. The firm has a fifty day moving average price of $122.40 and a 200 day moving average price of $111.24. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%. Encompass Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the firm earned $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Sell-side analysts predict that Encompass Health will post 6.08 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a dividend of $0.21 per share. The ex-dividend date is Thursday, October 1st. This represents a $0.84 annualized dividend and a dividend yield of 0.7%. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s payout ratio is presently 13.68%.

Insider Buying and Selling at Encompass Health

In related news, EVP John Darby sold 8,906 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.95, for a total value of $1,121,710.70. Following the transaction, the executive vice president directly owned 75,041 shares of the company’s stock, valued at $9,451,413.95. This trade represents a 10.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Mark J. Tarr sold 173,148 shares of Encompass Health stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the sale, the chief executive officer owned 267,814 shares in the company, valued at $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 186,912 shares of company stock valued at $23,434,845. Company insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Encompass Health

Large investors have recently bought and sold shares of the stock. ABLE Financial Group LLC grew its stake in Encompass Health by 1.9% during the 3rd quarter. ABLE Financial Group LLC now owns 16,730 shares of the company’s stock worth $2,033,000 after buying an additional 308 shares during the last quarter. Sivik Global Healthcare LLC increased its position in Encompass Health by 166.7% during the third quarter. Sivik Global Healthcare LLC now owns 40,000 shares of the company’s stock worth $4,860,000 after buying an additional 25,000 shares during the period. Wedmont Private Capital acquired a new position in Encompass Health during the third quarter worth approximately $205,000. Diversified Management Inc. purchased a new stake in Encompass Health in the third quarter valued at approximately $230,000. Finally, GAMMA Investing LLC lifted its stake in Encompass Health by 10.1% in the third quarter. GAMMA Investing LLC now owns 4,370 shares of the company’s stock valued at $531,000 after buying an additional 401 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation (NYSE:EHC) is a healthcare services company focused on inpatient rehabilitation. Through its network of rehabilitation hospitals, the company provides intensive medical and therapeutic care to patients recovering from conditions such as strokes, brain and spinal cord injuries, hip fractures, amputations, neurological disorders, and other disabling illnesses or injuries.

Its rehabilitation hospitals offer coordinated care from physicians, nurses, therapists, and other healthcare professionals.